Developer docs
API playgroundTry for free, no card

Search company profiles

FineHeart

Full company profile

uuid0000owi

Namestring
FineHeart
Legal namestring
FineHeart S.A.
Websiteurl
fineheart.fr
Company typeenum
Private
Founded yearint
2010
Descriptiontext

FineHeart is a French clinical-stage medical device company founded in 2010 and headquartered in Pessac (Bordeaux), developing the ICOMS FLOWMAKER, a fully implantable intraventricular cardiac output accelerator designed to treat advanced heart failure. The device is a catheter-deliverable intra-cardiac pump that synchronizes with the patient's native heartbeat to augment rather than replace natural ejection, powered by a miniaturized internal battery recharged through wireless transcutaneous energy transfer (TET), eliminating percutaneous drivelines and their associated infection risk. The technology is protected by 69+ patents globally including US Patent 11,097,093 covering device algorithms and granted Chinese patents, with potential applications spanning both temporary and permanent mechanical circulatory support.

The company's business model centers on Class III implantable hardware sales to hospitals and cardiac surgery centers through direct enterprise sales and hospital procurement processes following regulatory approval (CE marking in EU, FDA approval in US). As of late 2025, FineHeart had secured First-In-Human clinical trial authorizations from ANSM (France) and JAZMP (Slovenia) and announced successful first human implantations, but has not yet commercialized the product and generates no revenue. The company has cumulatively raised approximately €83 million through a Series C first closing (€35M, January 2026, co-led by Groupe Pasteur Mutualité and the EIC/EIB Fund) combined with €48M in non-dilutive IPCEI Tech4Cure grants, alongside prior Series B funding of €21M (2021), a €2.5M EIC Accelerator grant (2022), €7.8M France 2030 i-demo funding, and €750K ERDF support.

FineHeart has been designated lead partner of the IPCEI Tech4Cure consortium, a multi-country European initiative jointly notified by France, Hungary, Italy, Latvia, Slovakia, and Slovenia to structure the European Active Implantable Medical Devices sector. The company operates a 900 m² production facility in Pessac including a 100 m² ISO 7 cleanroom, is pursuing ISO 13485:2016 certification and EU MDR compliance, and is staffed by 11-50 employees including senior executives with prior tenures at Medtronic, GE Healthcare, Zimmer Biomet, and Pixium Vision.

Short descriptiontext

FineHeart is a French clinical-stage medical device company developing the ICOMS FLOWMAKER, a fully implantable intraventricular cardiac output accelerator that synchronizes with the native heartbeat via wireless power transfer to treat advanced heart failure patients in hospitals and cardiac surgery centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPessac, France
HQ citystring
Pessac
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable cardiac devices, heart failure treatment, ventricular assist devices, wireless power transfer, cardiac output accelerator
Industry2 codes
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Ventricular Assist Devices (Cardiac Assist Devices)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

FineHeart will generate revenue through the sale of the FlowMaker implantable cardiac device to hospitals and cardiac surgery centers. As a Class III implantable medical device, pricing will be determined through hospital procurement and reimbursement processes.

fineheart.fr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Pricing details1 tier
1No public pricing tiers available
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed

fineheart.fr
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

FineHeart develops and manufactures the ICOMS FLOWMAKER®, a fully implantable intraventricular cardiac output accelerator that synchronizes to the patient's native heartbeat to restore natural cardiac pumping capacity. The device is powered by a miniaturized internal battery recharged through wireless transcutaneous energy transfer (TET), eliminating percutaneous drivelines and reducing infection risk. It is offered alongside a catheter-based delivery system for minimally invasive implantation, targeting advanced heart failure patients in hospital and cardiac surgery center settings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First-In-Human clinical trials authorized by ANSM (France) and JAZMP (Slovenia)
+2 more records
Product overview1 text field

FineHeart offers a unified product ecosystem centered on the ICOMS FLOWMAKER®, the world's first fully implantable cardiac output accelerator for advanced heart failure. This system combines the main device with a wireless transcutaneous energy transfer (TET) system for power and a dedicated delivery system for minimally invasive implantation. The technology synchronizes with the native heartbeat to restore natural cardiac pumping capacity without the complications of traditional ventricular assist devices.

Product and service3 records
1ICOMS FLOWMAKER®
CategoryImplantable cardiac assist device (core product)
Description

The world's first fully implantable cardiac output accelerator designed to treat advanced heart failure. It is an intraventricular flow accelerator synchronized to the native heartbeat that restores the natural heart's pumping capacity, powered by a miniaturized internal battery recharged wirelessly via transcutaneous energy transfer. It is intended for hospitals and cardiac surgery centers treating advanced heart failure patients as a Class III implantable medical device.

2Wireless Transcutaneous Energy Transfer (TET) System
CategoryWireless power delivery system for implantable device (core product)
Description

Wireless power transfer system for powering the ICOMS FLOWMAKER® implantable heart pump, eliminating the need for percutaneous drivelines and reducing infection risk. The internal battery is rechargeable through the skin via a wireless external source.

3Delivery System
CategoryImplantation accessory (accessory)
Description

Catheter-based delivery system for minimally invasive implantation of the ICOMS FLOWMAKER® device during beating-heart procedures, designed for use by cardiac surgeons and interventional cardiology teams.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1IPCEI Tech4Cure Consortium
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-07-24
Description

FineHeart serves as lead partner of IPCEI Tech4Cure (Important Project of Common European Interest) jointly notified by France, Hungary, Italy, Latvia, Slovakia, and Slovenia. The €48 million grant supports structuring the European Active Implantable Medical Devices sector focusing on miniaturization, energy reduction, and long-term reliability.

biospace.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Abbott
TypeDirect peer
Description

Abbott manufactures HeartMate 3, the market-leading left ventricular assist device (LVAD) for advanced heart failure. HeartMate 3 is the primary incumbent that FineHeart's FlowMaker aims to disrupt with its fully implantable, driveline-free architecture.

2Carmat
TypeDirect peer
Description

Carmat is a French clinical-stage company developing Aeson, a total artificial heart for patients with end-stage biventricular heart failure. Both companies are French clinical-stage cardiac implant developers addressing severe heart failure with novel mechanical support architectures.

TypeDirect peer
Description

CorWave is a French medtech company developing a novel implantable LVAD using a wave membrane pump technology. It is the closest French peer to FineHeart in developing next-generation mechanical circulatory support devices.

TypeBroad incumbent
Description

Medtronic historically competed in the LVAD market with the HVAD system (now discontinued) and remains a major cardiac device incumbent. Medtronic's scale, clinical infrastructure, and existing heart failure portfolio position it as a potential acquirer or competitor to FineHeart.

TypeDirect peer
Description

Berlin Heart develops ventricular assist devices (VADs) for pediatric and adult patients, including the EXCOR and newer implantable systems. It directly competes in the mechanical circulatory support space targeting heart failure patients.

6ReliantHeart
TypeDirect peer
Description

ReliantHeart develops the HeartAssist5 and aVAD, a next-generation LVAD with remote monitoring capabilities. It competes in the same advanced heart failure mechanical support category as FineHeart.

TypeDirect peer
Description

SynCardia manufactures the SynCardia Total Artificial Heart, a permanent mechanical replacement for both ventricles in end-stage heart failure patients. It competes in the severe heart failure treatment space served by FineHeart.

8Evaheart
TypeDirect peer
Description

Evaheart develops the EVAHEART LVAD, a continuous-flow left ventricular assist system for advanced heart failure patients. It is a direct competitor in the implantable mechanical circulatory support device category.

TypeEmerging player
Description

Calon Cardio is a UK-based medtech developing the MiniVAD, a next-generation miniaturized ventricular assist device. It competes with FineHeart in developing smaller, less invasive mechanical circulatory support technologies.

TypeEmerging player
Description

CH Biomedical is an emerging Chinese-American LVAD developer focused on next-generation ventricular assist technologies. It is a relevant emerging competitor in the implantable mechanical heart support category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FineHeart

Ventricular Assist Devices (Cardiac Assist Devices)fineheart.fr

FineHeart is a French clinical-stage medical device company developing the ICOMS FLOWMAKER, a fully implantable intraventricular cardiac output accelerator that synchronizes with the native heartbeat via wireless power transfer to treat advanced heart failure patients in hospitals and cardiac surgery centers.

What FineHeart does

FineHeart is a French clinical-stage medical device company founded in 2010 and headquartered in Pessac (Bordeaux), developing the ICOMS FLOWMAKER, a fully implantable intraventricular cardiac output accelerator designed to treat advanced heart failure. The device is a catheter-deliverable intra-cardiac pump that synchronizes with the patient's native heartbeat to augment rather than replace natural ejection, powered by a miniaturized internal battery recharged through wireless transcutaneous energy transfer (TET), eliminating percutaneous drivelines and their associated infection risk. The technology is protected by 69+ patents globally including US Patent 11,097,093 covering device algorithms and granted Chinese patents, with potential applications spanning both temporary and permanent mechanical circulatory support.

The company's business model centers on Class III implantable hardware sales to hospitals and cardiac surgery centers through direct enterprise sales and hospital procurement processes following regulatory approval (CE marking in EU, FDA approval in US). As of late 2025, FineHeart had secured First-In-Human clinical trial authorizations from ANSM (France) and JAZMP (Slovenia) and announced successful first human implantations, but has not yet commercialized the product and generates no revenue. The company has cumulatively raised approximately €83 million through a Series C first closing (€35M, January 2026, co-led by Groupe Pasteur Mutualité and the EIC/EIB Fund) combined with €48M in non-dilutive IPCEI Tech4Cure grants, alongside prior Series B funding of €21M (2021), a €2.5M EIC Accelerator grant (2022), €7.8M France 2030 i-demo funding, and €750K ERDF support.

FineHeart has been designated lead partner of the IPCEI Tech4Cure consortium, a multi-country European initiative jointly notified by France, Hungary, Italy, Latvia, Slovakia, and Slovenia to structure the European Active Implantable Medical Devices sector. The company operates a 900 m² production facility in Pessac including a 100 m² ISO 7 cleanroom, is pursuing ISO 13485:2016 certification and EU MDR compliance, and is staffed by 11-50 employees including senior executives with prior tenures at Medtronic, GE Healthcare, Zimmer Biomet, and Pixium Vision.

FineHeart firmographics

Firmographics
Name
FineHeart
Legal name
FineHeart S.A.
Website
https://fineheart.fr
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
FineHeart is a French clinical-stage medical device company developing the ICOMS FLOWMAKER, a fully implantable intraventricular cardiac output accelerator that synchronizes with the native heartbeat via wireless power transfer to treat advanced heart failure patients in hospitals and cardiac surgery centers.
Ownership category
akta.pro rank

FineHeart industry classification

Industry
Product category
Ventricular Assist Devices (Cardiac Assist Devices)
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Implantable cardiac devices
  • Heart failure treatment
  • Ventricular assist devices
  • Wireless power transfer
  • Cardiac output accelerator

Where FineHeart is headquartered

Location

Headquarters

HQ city
Pessac
HQ country
France
HQ region
Europe

Offices2 records

Markets served

FineHeart business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: FineHeart will generate revenue through the sale of the FlowMaker implantable cardiac device to hospitals and cardiac surgery centers. As a Class III implantable medical device, pricing will be determined through hospital procurement and reimbursement processes.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractNo public pricing tiers available

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

FineHeart product offering

Product offering

Core offering

FineHeart develops and manufactures the ICOMS FLOWMAKER®, a fully implantable intraventricular cardiac output accelerator that synchronizes to the patient's native heartbeat to restore natural cardiac pumping capacity. The device is powered by a miniaturized internal battery recharged through wireless transcutaneous energy transfer (TET), eliminating percutaneous drivelines and reducing infection risk. It is offered alongside a catheter-based delivery system for minimally invasive implantation, targeting advanced heart failure patients in hospital and cardiac surgery center settings.

Product overview

FineHeart offers a unified product ecosystem centered on the ICOMS FLOWMAKER®, the world's first fully implantable cardiac output accelerator for advanced heart failure. This system combines the main device with a wireless transcutaneous energy transfer (TET) system for power and a dedicated delivery system for minimally invasive implantation. The technology synchronizes with the native heartbeat to restore natural cardiac pumping capacity without the complications of traditional ventricular assist devices.

Differentiator

Problem solved

Functional benefit

Products and services

  • ICOMS FLOWMAKER® The world's first fully implantable cardiac output accelerator designed to treat advanced heart failure. It is an intraventricular flow accelerator synchronized to the native heartbeat that restores the natural heart's pumping capacity, powered by a miniaturized internal battery recharged wirelessly via transcutaneous energy transfer. It is intended for hospitals and cardiac surgery centers treating advanced heart failure patients as a Class III implantable medical device.
  • Wireless Transcutaneous Energy Transfer (TET) System Wireless power transfer system for powering the ICOMS FLOWMAKER® implantable heart pump, eliminating the need for percutaneous drivelines and reducing infection risk. The internal battery is rechargeable through the skin via a wireless external source.
  • Delivery System Catheter-based delivery system for minimally invasive implantation of the ICOMS FLOWMAKER® device during beating-heart procedures, designed for use by cardiac surgeons and interventional cardiology teams.

Quantifiable outcome

  • First-In-Human clinical trials authorized by ANSM (France) and JAZMP (Slovenia)
  • +2 more outcomes

Companies that use FineHeart

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

FineHeart technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

FineHeart partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • IPCEI Tech4Cure ConsortiumflagshipStrategic or Co-development Partner · 24 July 2025FineHeart serves as lead partner of IPCEI Tech4Cure (Important Project of Common European Interest) jointly notified by France, Hungary, Italy, Latvia, Slovakia, and Slovenia. The €48 million grant supports structuring the European Active Implantable Medical Devices sector focusing on miniaturization, energy reduction, and long-term reliability.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

FineHeart competitors and assessment

Company assessment

Direct peers

  • Abbott: Abbott manufactures HeartMate 3, the market-leading left ventricular assist device (LVAD) for advanced heart failure. HeartMate 3 is the primary incumbent that FineHeart's FlowMaker aims to disrupt with its fully implantable, driveline-free architecture.
  • Carmat: Carmat is a French clinical-stage company developing Aeson, a total artificial heart for patients with end-stage biventricular heart failure. Both companies are French clinical-stage cardiac implant developers addressing severe heart failure with novel mechanical support architectures.
  • CorWave: CorWave is a French medtech company developing a novel implantable LVAD using a wave membrane pump technology. It is the closest French peer to FineHeart in developing next-generation mechanical circulatory support devices.
  • Berlin Heart: Berlin Heart develops ventricular assist devices (VADs) for pediatric and adult patients, including the EXCOR and newer implantable systems. It directly competes in the mechanical circulatory support space targeting heart failure patients.
  • ReliantHeart: ReliantHeart develops the HeartAssist5 and aVAD, a next-generation LVAD with remote monitoring capabilities. It competes in the same advanced heart failure mechanical support category as FineHeart.
  • SynCardia Systems: SynCardia manufactures the SynCardia Total Artificial Heart, a permanent mechanical replacement for both ventricles in end-stage heart failure patients. It competes in the severe heart failure treatment space served by FineHeart.
  • Evaheart: Evaheart develops the EVAHEART LVAD, a continuous-flow left ventricular assist system for advanced heart failure patients. It is a direct competitor in the implantable mechanical circulatory support device category.

Broad incumbents

  • Medtronic: Medtronic historically competed in the LVAD market with the HVAD system (now discontinued) and remains a major cardiac device incumbent. Medtronic's scale, clinical infrastructure, and existing heart failure portfolio position it as a potential acquirer or competitor to FineHeart.

Emerging players

  • Calon Cardio: Calon Cardio is a UK-based medtech developing the MiniVAD, a next-generation miniaturized ventricular assist device. It competes with FineHeart in developing smaller, less invasive mechanical circulatory support technologies.
  • CH Biomedical: CH Biomedical is an emerging Chinese-American LVAD developer focused on next-generation ventricular assist technologies. It is a relevant emerging competitor in the implantable mechanical heart support category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

FineHeart social profiles

Digital presence

FineHeart compliance and trust

Trust signal

Compliance4 records

FineHeart financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FineHeart leadership team

Management profile

Number of profiles

Profiles12 records

FineHeart funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FineHeart M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FineHeart

What does FineHeart do?

FineHeart develops and manufactures the ICOMS FLOWMAKER®, a fully implantable intraventricular cardiac output accelerator that synchronizes to the patient's native heartbeat to restore natural cardiac pumping capacity. The device is powered by a miniaturized internal battery recharged through wireless transcutaneous energy transfer (TET), eliminating percutaneous drivelines and reducing infection risk. It is offered alongside a catheter-based delivery system for minimally invasive implantation, targeting advanced heart failure patients in hospital and cardiac surgery center settings.

Is FineHeart a public or private company?

FineHeart is a private company. It is classified as venture growth investor backed and is currently operating.

When was FineHeart founded?

FineHeart was founded in 2010. It employs 51 to 100 people.

Where is FineHeart based?

FineHeart is headquartered in Pessac, France, in the Europe region.

How does FineHeart make money?

One revenue line is on record: medical Device Sales.

Who are FineHeart's main competitors?

Direct peers on record are Abbott, Carmat, CorWave, Berlin Heart, ReliantHeart, SynCardia Systems and Evaheart. Medtronic is listed as a broad incumbent. Emerging players are Calon Cardio and CH Biomedical.

Does FineHeart have an API?

No public API is recorded for FineHeart.

What industry is FineHeart in?

FineHeart's product category is Ventricular Assist Devices (Cardiac Assist Devices). Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech.euFrance's top-funded tech companies in H1 2026France's top-funded tech companies in H1 2026 were led by Eutelsat's €975M debt financing, AMI's $1B seed round, and Mistral AI's $830M debt raise. AI, space, fintech, and healthcare dominated, with large transactions shaping the landscape.Business Wire BlogFineHeart strengthens its Board of Directors with the appointment of Pierre ChauvineauFineHeart appointed Pierre Chauvineau to its Board of Directors, an international medtech executive with over 35 years of experience. The appointment supports FineHeart's scale-up of FlowMaker®, a therapy for advanced heart failure, as the company accelerates clinical and industrial programs. Chauvineau brings expertise in international market access and cardiovascular sector leadership.Pulse 2.0FineHeart: €83 Million Secured To Develop Implantable Solutions For CardiologyFineHeart secured €83 million in financing, including a €35 million Series C closing and €48 million in IPCEI Tech4Cure grants. The funds will advance its FlowMaker device, a fully implantable cardiac output accelerator for advanced heart failure, targeting about 50,000 patients initially.FinSMEsFineHeart Raises €35M in Series C First Closing; Receives €48M in GrantsFineHeart, a French cardiology device company, raised €35M in its first Series C closing and received €48M in grants. The funding will accelerate development of FlowMaker, a fully implantable cardiac output accelerator for advanced heart failure. The company targets a potential market of over €5 billion.BioSpaceFineHeart Secures €83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)FineHeart, a clinical-stage medical technology company based in Bordeaux, France, has completed an €83 million financing round combining €35 million in Series C funding and €48 million in IPCEI Tech4Cure grants to accelerate development of its FlowMaker® fully implantable cardiac device for advanced heart failure treatment. The Series C first closing was co-led by new investors including Groupe Pasteur Mutualité and the European Innovation Council, with participation from existing shareholders. FineHeart will use the IPCEI funding as lead partner to structure the European Active Implantable Medical Devices sector, focusing on miniaturization, energy reduction, and long-term reliability of implantable systems.EU-StartupsFrench MedTech FineHeart raises €83 million in private capital and EU grants to fight advanced heart failureBordeaux and Tours-based FineHeart, a clinical-stage medical device company developing cardiovascular technologies, has completed a €35 million first closing of its Series C financing round with investors including Groupe Pasteur Mutualité, Groupe Etchart, FH Founders, Lurra, IRDI, Groupe Doliam, and NACO, alongside the European Innovation Council's EIB fund. The company has also secured €48 million in grants from the Important Project of Common European Interest (IPCEI) Tech4Cure programme, bringing its total funding to €83 million. FineHeart's core product is the FlowMaker®, described as the world's first fully implantable cardiac output accelerator for treating advanced heart failure, which the company positions as a hybrid between a pacemaker and a cardiac assist device.BebeezFrench MedTech FineHeart raises €83M in private capital and EU grants to fight advanced heart failure – BeBeez InternationalBordeaux and Tours-based FineHeart, a clinical-stage medical device company, announced the completion of a €35 million first closing of its Series C financing round, with participation from investors including Groupe Pasteur Mutualité, Groupe Etchart, and the European Innovation Council's EIB fund. The company has also secured €48 million in grants from the IPCEI Tech4Cure programme, bringing its total secured funding to €83 million. FineHeart's core product is FlowMaker®, claimed to be the world's first fully implantable cardiac output accelerator designed to treat advanced heart failure, and the company was designated as lead partner of the IPCEI Tech4Cure project approved by the European Commission.BeinsureMedTech FineHeart raised €35mn Series C and €48 mn in EU grantsFineHeart, a clinical-stage medical device company based in Bordeaux and Tours, completed a €35 million first closing of its Series C round as part of an €83 million financing package for advanced heart failure treatment. The company also secured €48 million in non-dilutive grants under the EU IPCEI Tech4Cure program, positioning itself as lead partner in a European initiative to strengthen the active implantable medical devices sector. FineHeart's lead device FlowMaker is a fully implantable cardiac output accelerator designed for minimally invasive beating-heart procedures.AijournFineHeart Secures €83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)FineHeart, a clinical-stage medical technology company based in Bordeaux and Tours, France, completed a €35 million first closing of its Series C financing round with investors including Groupe Pasteur Mutualité, Groupe Etchart, and the European Innovation Council (EIC) EIB fund. The company also secured €48 million in grants from the IPCEI Tech4Cure program as lead partner in structuring the European Active Implantable Medical Devices sector, bringing its total funding to €83 million. The capital will accelerate the industrialization and clinical development of FlowMaker®, the world's first fully implantable cardiac output accelerator designed to treat advanced heart failure.Medical Device and Diagnostic industry25 Medtech Startups You Need to KnowThe MedTech Innovator Competition announced its winners last month at The MedTech Conference in Philadelphia, highlighting 25 early-stage companies with potential to impact healthcare. Sana Health secured first place and received a $350,000 grand prize to further its mission. AblaCare was awarded second place, while CroiValve, FineHeart, and Spect were recognized as runners-up, each receiving $25,000.